Catalent Welcomes The Announcement By Biohaven Of The FDA’s Acceptance Of 505(b)(2) NDA Filing For BHV-0223

Catalent welcomes the announcement by its partner, Biohaven, of the FDA’s Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Learn More